HRP20182017T4 - Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe - Google Patents
Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe Download PDFInfo
- Publication number
- HRP20182017T4 HRP20182017T4 HRP20182017TT HRP20182017T HRP20182017T4 HR P20182017 T4 HRP20182017 T4 HR P20182017T4 HR P20182017T T HRP20182017T T HR P20182017TT HR P20182017 T HRP20182017 T HR P20182017T HR P20182017 T4 HRP20182017 T4 HR P20182017T4
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- binding fragment
- antibody
- seq
- alpha toxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/709—Toxin induced
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
Claims (17)
1. Izolirano protutijelo ili njegov ulomak koji veže antigen, naznačeno time što se izolirano protutijelo ili njegov ulomak koji veže antigen imunospecifično veže na polipeptid alfa toksina koji stvara Staphylococcus aureus i sadrži:
(a) VH CDR1 sadrži sekvencu aminokiseline iz SEQ ID NO: 69;
(b) VH CDR2 sadrži sekvencu aminokiseline iz SEQ ID NO: 70;
(c) VH CDR3 sadrži sekvencu aminokiseline iz SEQ ID NO: 71;
(d) VL CDR1 sadrži sekvencu aminokiseline iz SEQ ID NO: 1;
(e) VL CDR2 sadrži sekvencu aminokiseline iz SEQ ID NO: 2, i
(f) VL CDR3 sadrži sekvencu aminokiseline iz SEQ ID NO: 68 .
2. Izolirano protutijelo ili ulomak koji veže antigen prema zahtjevu 1, naznačeno time što sadrži varijabilnu domenu teškog lanca koja je barem 90% identična s aminokiselinskom sekvencom iz SEQ ID NO: 57, i varijabilnu domenu laganog lanca koja je barem 90% identična sa aminokiselinskom sekvencom iz SEQ ID NO: 58.
3. Protutijelo ili ulomak koji veže antigen prema zahtjevu 2, naznačeno time što VH i VL odgovaraju sekvencama aminokiselina iz SEQ ID NO: 57 i 58.
4. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 3, naznačeno time što izolirano protutijelo ili njegov ulomak koji veže antigen ima jednu ili više značajki odabranih iz skupine koju čine:
(a) konstanta afiniteta (KD) za alfa toksin od oko 13 nM ili manje;
(b) veže se na monomere alfa toksina, ali ne inhibira vezanje alfa toksina na receptor alfa toksina;
(c) inhibira stvaranje oligomera alfa toksina za barem 50%, 60%, 70%, 80%, 90%, ili 95%;
(d) smanjuje citolitičku aktivnost alfa toksina za barem 50%, 60%, 70%, 80%, 90%, ili 95% (npr.., određeno pomoću testova lize stanice i hemolize stanice); i
(e) smanjuje infiltraciju stanica i pro-upalno oslobađanje citokina (npr., u modelu životinjske upale pluća).
5. Pripravak naznačen time što sadrži protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4.
6. Pripravak prema zahtjevu 5, naznačen time što pripravak sadrži dodatno sredstvo, pri čemu je dodatno sredstvo antibiotik.
7. Komplet, naznačen time što sadrži
(a) protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu ili 6;
(b) upute za uporabu pripravka ili smjernice za dobivanje uputa za uporabu pripravka.
8. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu 5 ili 6, naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje upalom pluća kod subjekta.
9. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu 5 ili 6, naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje stanjem infekcije kože kod subjekta.
10. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu 5 ili 6, naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje upalom pluća ili stanjem infekcije kože kod subjekta prema zahtjevu 8 ili 9 inhibicijom stvaranja oligomera alfa toksina Staphylococcus aureus za barem 50%, 60%, 70%, 80%, 90% ili 95%.
11. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 naznačeno time što se imuno specifično veže na ulomak alfa toksina koji stvara Staphylococcus aureus iz SEQ ID NO: 39.
12. Izolirano protutijelo ili ulomak koji veže antigen prema zahtjevu 11, naznačeno time što se protutijelo ili njegov ulomak koji veže antigen veže na ulomak koji sadrži aminokiseline 261-272 iz SEQ ID NO: 39 i/ili aminokiseline 173-201 iz SEQ ID NO: 39.
13. Izolirano protutijelo ili ulomak koji veže antigen prema zahtjevu 12, naznačeno time što se protutijelo ili njegov ulomak koji veže antigen veže se na ulomak koji sadrži aminokiseline 261-272 iz SEQ ID NO: 39 i aminokiseline 173-201 iz SEQ ID NO: 39.
14. Izolirano protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4, naznačeno time što protutijelo ili njegov ulomak koji veže antigen sprječava nastanak heptamera alfa toksina, i pri čemu je navedeno protutijelo ili ulomak koji veže antigen u kontaktu s ostacima na položajima T261, T263, N264, K266, K271, N177, W179, G180, P181, Y182, D183, D185, S186, W187, N188, P189, V190, Y191 i R200 od SEQ ID NO: 39.
15. Pripravak prema zahtjevu 6, naznačen time što je antibiotik vankomicin.
16. Izolirano protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 11 do 14 naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje upalom pluća ili stanjem infekcije kože kod subjekta inhibicijom stvaranja oligomera alfa toksina.
17. Izolirano protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1-4 i 11-14 koje obuhvaća varijantu Fc regije, naznačeno time što izolirano protutijelo sadrži slijedeće sekvence
[image]
i
[image]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440581P | 2011-02-08 | 2011-02-08 | |
| EP12745207.6A EP2673373B3 (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| PCT/US2012/024201 WO2012109285A2 (en) | 2011-02-08 | 2012-02-07 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20182017T1 HRP20182017T1 (hr) | 2019-02-08 |
| HRP20182017T4 true HRP20182017T4 (hr) | 2021-08-20 |
Family
ID=46639171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20182017TT HRP20182017T4 (hr) | 2011-02-08 | 2012-02-07 | Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9527905B2 (hr) |
| EP (2) | EP3470526A3 (hr) |
| JP (4) | JP2014508748A (hr) |
| KR (1) | KR101993839B1 (hr) |
| CN (2) | CN107474133B (hr) |
| AU (1) | AU2012214531C1 (hr) |
| BR (1) | BR112013020086B1 (hr) |
| CA (1) | CA2826566C (hr) |
| CY (1) | CY1121389T1 (hr) |
| DK (1) | DK2673373T6 (hr) |
| ES (1) | ES2709065T7 (hr) |
| HR (1) | HRP20182017T4 (hr) |
| HU (1) | HUE040734T2 (hr) |
| LT (1) | LT2673373T (hr) |
| MX (3) | MX375113B (hr) |
| PL (1) | PL2673373T6 (hr) |
| PT (1) | PT2673373T (hr) |
| RS (1) | RS58190B2 (hr) |
| RU (1) | RU2620065C2 (hr) |
| SG (3) | SG10201913690SA (hr) |
| SI (1) | SI2673373T1 (hr) |
| SM (1) | SMT201800635T1 (hr) |
| TR (1) | TR201817932T4 (hr) |
| WO (1) | WO2012109285A2 (hr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2838211C (en) | 2011-06-10 | 2023-08-01 | Medimmmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
| HUE050985T2 (hu) | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| EP2793944B1 (en) | 2011-12-23 | 2025-10-08 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| KR20150082367A (ko) * | 2012-11-06 | 2015-07-15 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법 |
| KR20150092738A (ko) * | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) * | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| CN105873946A (zh) * | 2013-10-17 | 2016-08-17 | 阿尔萨尼斯生物科学有限责任公司 | 交叉反应性金黄色葡萄球菌抗体序列 |
| US10487140B2 (en) | 2014-01-14 | 2019-11-26 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| WO2016023943A1 (en) * | 2014-08-12 | 2016-02-18 | Arsanis Biosciences Gmbh | Predicting s. aureus disease |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| JP6889701B2 (ja) | 2015-09-24 | 2021-06-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルファ溶血素バリアント |
| WO2017075188A2 (en) * | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| MA47468A (fr) | 2017-02-09 | 2019-12-18 | Bluefin Biomedicine Inc | Anticorps anti-ilt3 et conjugués anticorps-médicament |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN109384844B (zh) * | 2017-08-04 | 2020-12-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用 |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| US11396542B2 (en) | 2018-08-21 | 2022-07-26 | Synkrino Biotherapeutics, Inc. | Astrotactin1-based compositions and pharmaceutical formulations |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| EP3864040A1 (en) | 2018-10-09 | 2021-08-18 | Medimmune, LLC | Antibodies directed against staphylococcus aureus leukotoxins |
| WO2020076789A2 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| TW202100549A (zh) * | 2019-03-13 | 2021-01-01 | 美商麥迪紐有限責任公司 | 降低金黃色葡萄球菌在定殖的患者中之感染 |
| WO2020210650A1 (en) | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| CN113444173A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| JP2024503425A (ja) * | 2021-01-11 | 2024-01-25 | 星濟生物（蘇州）有限公司 | 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用 |
| CN112941136B (zh) * | 2021-03-24 | 2023-04-28 | 成都欧林生物科技股份有限公司 | 一种重组金黄色葡萄球菌疫苗hi抗原蛋白的纯化方法 |
| CN114455048B (zh) * | 2022-03-02 | 2023-03-14 | 江苏微导纳米科技股份有限公司 | 一种桨杆 |
| WO2023208123A1 (zh) * | 2022-04-28 | 2023-11-02 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| CN116023486B (zh) * | 2023-01-10 | 2024-10-08 | 西北农林科技大学 | 金黄色葡萄球菌α-溶血素纳米抗体、制备方法及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| IL126544A (en) | 1996-04-25 | 2004-08-31 | Genicon Sciences Inc | Analyte assay using scattered-light detectable particles |
| AU2001276842B2 (en) | 2000-06-28 | 2007-04-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ES2338105T3 (es) | 2003-05-14 | 2010-05-04 | Kenta Biotech Ag | Anticuerpo monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 06 pseudomonas aeruginosa. |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| CN1942483B (zh) * | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| JP2008513406A (ja) * | 2004-09-22 | 2008-05-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| TW200813091A (en) * | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| EP2719397A1 (en) * | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| MX2009012891A (es) * | 2007-05-31 | 2009-12-10 | Merck & Co Inc | Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. |
| MX2010001918A (es) * | 2007-08-21 | 2010-03-11 | Amgen Inc | Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino. |
| AU2008292897B2 (en) * | 2007-08-31 | 2015-01-22 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US8172115B1 (en) | 2008-04-10 | 2012-05-08 | Spencer Forrest, Inc. | Hair building solids dispenser for one handed operation |
| WO2010003108A2 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| GB2467939A (en) * | 2009-02-20 | 2010-08-25 | Univ Sheffield | Removal of bacteria from media |
| BRPI1015567A2 (pt) * | 2009-06-22 | 2021-08-31 | Wyeth Llc | Composições imunogênicas de antígenos de staphylococcus aureus |
| CN104968797B (zh) | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
-
2012
- 2012-02-07 SG SG10201913690SA patent/SG10201913690SA/en unknown
- 2012-02-07 BR BR112013020086-3A patent/BR112013020086B1/pt active IP Right Grant
- 2012-02-07 RS RS20181450A patent/RS58190B2/sr unknown
- 2012-02-07 EP EP18190790.8A patent/EP3470526A3/en active Pending
- 2012-02-07 CN CN201710480750.7A patent/CN107474133B/zh active Active
- 2012-02-07 HU HUE12745207A patent/HUE040734T2/hu unknown
- 2012-02-07 AU AU2012214531A patent/AU2012214531C1/en active Active
- 2012-02-07 PL PL12745207T patent/PL2673373T6/pl unknown
- 2012-02-07 WO PCT/US2012/024201 patent/WO2012109285A2/en not_active Ceased
- 2012-02-07 RU RU2013141134A patent/RU2620065C2/ru active
- 2012-02-07 PT PT12745207T patent/PT2673373T/pt unknown
- 2012-02-07 KR KR1020137023512A patent/KR101993839B1/ko active Active
- 2012-02-07 MX MX2017001101A patent/MX375113B/es unknown
- 2012-02-07 EP EP12745207.6A patent/EP2673373B3/en active Active
- 2012-02-07 JP JP2013553501A patent/JP2014508748A/ja active Pending
- 2012-02-07 CA CA2826566A patent/CA2826566C/en active Active
- 2012-02-07 ES ES12745207T patent/ES2709065T7/es active Active
- 2012-02-07 CN CN201280007986.4A patent/CN103443285B9/zh active Active
- 2012-02-07 TR TR2018/17932T patent/TR201817932T4/en unknown
- 2012-02-07 US US13/983,804 patent/US9527905B2/en active Active
- 2012-02-07 DK DK12745207.6T patent/DK2673373T6/da active
- 2012-02-07 HR HRP20182017TT patent/HRP20182017T4/hr unknown
- 2012-02-07 SM SM20180635T patent/SMT201800635T1/it unknown
- 2012-02-07 SG SG2013057831A patent/SG192212A1/en unknown
- 2012-02-07 MX MX2013009127A patent/MX345285B/es active IP Right Grant
- 2012-02-07 LT LTEP12745207.6T patent/LT2673373T/lt unknown
- 2012-02-07 SG SG10201600899PA patent/SG10201600899PA/en unknown
- 2012-02-07 SI SI201231470T patent/SI2673373T1/sl unknown
-
2013
- 2013-08-07 MX MX2020009700A patent/MX2020009700A/es unknown
-
2017
- 2017-02-13 JP JP2017023905A patent/JP6367393B2/ja active Active
-
2018
- 2018-07-04 JP JP2018127340A patent/JP6723293B2/ja active Active
- 2018-11-28 CY CY20181101266T patent/CY1121389T1/el unknown
-
2020
- 2020-06-23 JP JP2020108083A patent/JP7047017B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20182017T4 (hr) | Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe | |
| JP2014508748A5 (hr) | ||
| JP2020037555A5 (hr) | ||
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| JP2009225799A5 (hr) | ||
| JP2012511329A5 (hr) | ||
| JP2016507470A5 (hr) | ||
| JP2019059786A5 (hr) | ||
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2011509245A5 (hr) | ||
| SI2857418T1 (en) | Antibodies against Clostridium difficile toxins and uses thereof | |
| RU2015121617A (ru) | Способы лечения заболеваний, ассоциированных с s. aureus | |
| JP2016513682A5 (hr) | ||
| HRP20250602T1 (hr) | Antitijela koja se vežu na sortilin i inhibiraju vezanje progranulina | |
| JP2017518258A5 (hr) | ||
| RU2010126078A (ru) | Антитело против nr10 и его применение | |
| HRP20210778T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| JP2017510567A5 (hr) | ||
| JP2015509960A5 (hr) | ||
| HRP20190917T1 (hr) | NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE | |
| JP2020502198A5 (hr) | ||
| JP2016530223A5 (hr) |